➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Express Scripts
Merck
Baxter
Colorcon

Last Updated: May 6, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022253

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 022253 describes VIMPAT, which is a drug marketed by Ucb Inc and is included in three NDAs. It is available from two suppliers. There is one patent protecting this drug and three Paragraph IV challenges. Additional details are available on the VIMPAT profile page.

The generic ingredient in VIMPAT is lacosamide. There are twenty-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
Summary for 022253
Tradename:VIMPAT
Applicant:Ucb Inc
Ingredient:lacosamide
Patents:1
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 022253
Generic Entry Date for 022253*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022253
Suppliers and Packaging for NDA: 022253
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIMPAT lacosamide TABLET;ORAL 022253 NDA UCB, Inc. 0131-2470 0131-2470-99 1 BLISTER PACK in 1 CARTON (0131-2470-99) > 1 KIT in 1 BLISTER PACK
VIMPAT lacosamide TABLET;ORAL 022253 NDA UCB, Inc. 0131-2477 0131-2477-35 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0131-2477-35)
Paragraph IV (Patent) Challenges for 022253
Tradename Dosage Ingredient NDA Submissiondate
VIMPAT TABLET;ORAL lacosamide 022253 2012-10-29

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG
Approval Date:Oct 28, 2008TE:RLD:Yes
Patent:  Get Started for $10Patent Expiration:Mar 17, 2022Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Oct 28, 2008TE:RLD:Yes
Patent:  Get Started for $10Patent Expiration:Mar 17, 2022Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength150MG
Approval Date:Oct 28, 2008TE:RLD:Yes
Patent:  Get Started for $10Patent Expiration:Mar 17, 2022Product Flag?YSubstance Flag?YDelist Request?

Expired US Patents for NDA 022253

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-004 Oct 28, 2008   Get Started for $10   Get Started for $10
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-001 Oct 28, 2008   Get Started for $10   Get Started for $10
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-003 Oct 28, 2008   Get Started for $10   Get Started for $10
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-002 Oct 28, 2008   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Boehringer Ingelheim
Express Scripts
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.